The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 29, 2010
Filed:
Sep. 20, 2005
Motohide Satoh, Osaka, JP;
Hisateru Aramaki, Osaka, JP;
Hiroshi Nakamura, Osaka, JP;
Masafumi Inoue, Osaka, JP;
Hiroshi Kawakami, Osaka, JP;
Hisashi Shinkai, Osaka, JP;
Yuji Matsuzaki, Osaka, JP;
Kazunobu Yamataka, Osaka, JP;
Motohide Satoh, Osaka, JP;
Hisateru Aramaki, Osaka, JP;
Hiroshi Nakamura, Osaka, JP;
Masafumi Inoue, Osaka, JP;
Hiroshi Kawakami, Osaka, JP;
Hisashi Shinkai, Osaka, JP;
Yuji Matsuzaki, Osaka, JP;
Kazunobu Yamataka, Osaka, JP;
Japan Tobacco Inc., Tokyo, JP;
Abstract
A pharmaceutical agent having an anti-HIV action, particularly, a pharmaceutical agent having an integrase inhibitory action, is provided. The present invention relates to a quinolizinone compound represented by the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compounds can become a more effective anti-HIV agent. Since the compound has a high inhibitory activity specific for integrases, the compound can provide a safe pharmaceutical agent for human with a fewer side effects.